PIK3CA and laryngotracheoesophageal cleft: Given the unsuccessful results obtained from these published studies, only one ongoing clinical trial is currently seeking to evaluate the efficacy of a novel PI3K inhibitor (pictilisib) in patients with LC and with occurring alterations in the PIK3CA gene (Supplementary Table S1).